Thalidomide
- Generic Name
- Thalidomide
- Brand Names
- Thalomid, Thalidomide BMS (previously Thalidomide Celgene), Thalidomide Lipomed
- Drug Type
- Small Molecule
- Chemical Formula
- C13H10N2O4
- CAS Number
- 50-35-1
- Unique Ingredient Identifier
- 4Z8R6ORS6L
- Background
A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators li...
- Indication
Thalidomide is primarily used for the acute treatment and maintenance therapy to prevent and suppress the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL).
- Associated Conditions
- Aphthous Stomatitis, Chronic Graft-Versus-Host Disease, Erythema Nodosum Leprosum, Multiple Myeloma (MM), Primary Amyloidosis, Uremic Pruritus, Waldenström's Macroglobulinemia (WM), Moderate Erythema nodosum leprosum, Refractory Graft versus host disease, Severe Erythema nodosum leprosum, Treatment naive multiple myeloma
- Associated Therapies
- -
Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2012-02-23
- Last Posted Date
- 2015-01-26
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 7
- Registration Number
- NCT01537861
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
Phase II Trial Designed to Determine Efficacy and Safety of Bendamustine+Dexamethasone+Thalidomide in R/R MM
- Conditions
- Interventions
- First Posted Date
- 2012-02-06
- Last Posted Date
- 2018-07-03
- Lead Sponsor
- Azienda Ospedaliera di Bolzano
- Target Recruit Count
- 30
- Registration Number
- NCT01526694
- Locations
- 🇮🇹
AULSS 2 Feltre, Feltre, Italy
🇮🇹Ospedale Ca Foncello, Treviso, Italy
🇮🇹Ospedale dell'Angelo di Mestre, Mestre, Italy
Efficacy of Thalidomide in the Treatment of Hereditary Hemorrhagic Telangiectasia
- Conditions
- Interventions
- First Posted Date
- 2011-12-05
- Last Posted Date
- 2017-08-29
- Lead Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
- Target Recruit Count
- 31
- Registration Number
- NCT01485224
- Locations
- 🇮🇹
Clinica Medica 3, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy
Antiangiogenic Therapy for Children with Recurrent Medulloblastoma, Ependymoma and ATRT
- Conditions
- First Posted Date
- 2011-05-19
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 100
- Registration Number
- NCT01356290
- Locations
- 🇺🇸
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇺🇸Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸Helen DeVos Children's Hospital, Grand Rapids, Michigan, United States
THAL-DEX Incorporated Into Double PBSC Autotransplantation for Untreated Multiple Myeloma (MM)
- Conditions
- First Posted Date
- 2011-04-25
- Last Posted Date
- 2011-04-25
- Target Recruit Count
- 378
- Registration Number
- NCT01341262
VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM)
- First Posted Date
- 2010-06-02
- Last Posted Date
- 2012-07-20
- Lead Sponsor
- Michele Cavo
- Target Recruit Count
- 480
- Registration Number
- NCT01134484
- Locations
- 🇮🇹
AOU di Bologna Policlinico S.Orsola-Malpighi, UO di Ematologia, Bologna, Italy
Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (ThRiL) as Initial Treatment for Patients With CLL
- Conditions
- Interventions
- First Posted Date
- 2010-05-18
- Last Posted Date
- 2022-01-21
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 15
- Registration Number
- NCT01125176
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
Thalidomide for Patients With Mild to Moderate Alzheimer's Disease
- First Posted Date
- 2010-03-26
- Last Posted Date
- 2012-08-08
- Lead Sponsor
- Banner Health
- Target Recruit Count
- 20
- Registration Number
- NCT01094340
- Locations
- 🇺🇸
Banner Sun Health Research Institute, Sun City, Arizona, United States
Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma
- First Posted Date
- 2010-01-27
- Last Posted Date
- 2017-12-12
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 64
- Registration Number
- NCT01057225
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Medical University of South Carolina, Charleston, South Carolina, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- Drug: bortezomibDrug: cisplatinDrug: cyclophosphamideDrug: dexamethasoneDrug: doxorubicin hydrochlorideDrug: etoposideDrug: lenalidomideDrug: melphalanDrug: thalidomideGenetic: gene expression analysisGenetic: microarray analysisOther: laboratory biomarker analysisProcedure: autologous-autologous tandem hematopoietic stem cell transplantation
- First Posted Date
- 2010-01-25
- Last Posted Date
- 2015-03-06
- Lead Sponsor
- SWOG Cancer Research Network
- Registration Number
- NCT01055301
- Locations
- 🇺🇸
Harborview Medical Center, Seattle, Washington, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸Group Health Central Hospital, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.